{
    "clinical_study": {
        "@rank": "117835", 
        "arm_group": [
            {
                "arm_group_label": "Chemotherapy plus Radiation Therapy", 
                "arm_group_type": "Experimental", 
                "description": "Low dose fractionated radiation - 80cGy with chemotherapy"
            }, 
            {
                "arm_group_label": "Chemotherapy without Radiation", 
                "arm_group_type": "Active Comparator", 
                "description": "Chemotherapy only"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary hypothesis of this study is that hyper-radiosensitivity (HRS) seen at extremely\n      low doses of radiation can be exploited to enhance the effect of chemotherapy, and that this\n      effect differs from the cellular effect of higher, standard fractions of radiation used in\n      traditional radiation treatment paradigms."
        }, 
        "brief_title": "A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Head and Neck Cancer", 
            "Larynx"
        ], 
        "condition_browse": {
            "mesh_term": "Head and Neck Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed locally advanced head and neck cancer of\n             squamous type stage III, IVA and IV B  and select Stage II tumors of the BOT who are\n             appropriate for potentially curative therapy with chemoradiotherapy.\n\n          -  Measurable disease.\n\n          -  ECOG performance status of 0, 1 or 2\n\n          -  No prior chemotherapy for the current locally advanced SCCHN.\n\n          -  Age \u226518 years.\n\n          -  Life expectancy of greater than 3 months\n\n          -  Normal organ and marrow function measured within 14 days of registration as defined\n             below:\n\n               -  absolute neutrophil count \u2265 1,000/mcL\n\n               -  platelets \u2265 100,000/mcL\n\n               -  total bilirubin < institutional upper limit of normal\n\n               -  AST(SGOT \u2264 2.5 \u00d7 institutional upper limit of normal\n\n               -  Alkaline phosphatase \u2264 2.5 \u00d7 institutional upper limit of normal\n\n               -  creatinine within normal institutional limits\n\n          -  OR\n\n             o Creatinine clearance \u2265 60 mL/min/1.73 m2 for patients with creatinine levels above\n             institutional normal.\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control; abstinence) prior to study entry,\n             throughout the duration of active treatment and for 4 months after completion of\n             chemotherapy and radiation. Men treated or enrolled on this protocol must also agree\n             to use adequate contraception prior to the study, for the duration of active study\n             treatment, and for 4 months after completion of chemotherapy and radiation (both\n             induction and definitive) administration.\n\n          -  Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Exclusion Criteria:\n\n          -  Prior chemotherapy for SCCHN\n\n          -  Patients who are receiving any other investigational agents.\n\n          -  Patients with known brain metastases\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to Carboplatin or Docetaxel.\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements.\n\n          -  Pregnant women\n\n          -  HIV-positive patients on combination antiretroviral therapy\n\n          -  Other prior malignancy except adequately treated basal cell or squamous cell skin\n             cancer, in situ cervical cancer, adequately treated previous Stage I or II cancer\n             from which the patient is currently in complete remission or other cancer from which\n             the patient has been disease-free for 3 years.\n\n          -  Patients with nasopharynx or salivary gland primary site\n\n          -  Patients with distant metastatic disease (M1c)\n\n          -  Patients with grade II or greater peripheral neuropathy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02126969", 
            "org_study_id": "13-HN-24"
        }, 
        "intervention": [
            {
                "arm_group_label": "Chemotherapy plus Radiation Therapy", 
                "description": "Chemotherapy + 80 cGy of RT", 
                "intervention_name": "Low dose fractionated radiation - 80cGy with chemotherapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Chemotherapy without Radiation", 
                "description": "Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation", 
                "intervention_name": "Docetaxel  and Carboplatin AUC 6", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Cancer", 
            "Low dose radiation"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lexington", 
                    "country": "United States", 
                    "state": "Kentucky", 
                    "zip": "40536"
                }, 
                "name": "University of Kentucky, Markey Cancer Center"
            }, 
            "investigator": {
                "last_name": "Susanne M Arnold, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II Study of Docetaxel, Carboplatin With and Without Low Dose Radiation as Induction Therapy in Locally Advanced Head and Neck Cancer", 
        "overall_contact": {
            "email": "Smarno0@uky.edu", 
            "last_name": "Susanne M Arnold, MD", 
            "phone": "859-323-8043"
        }, 
        "overall_official": {
            "affiliation": "Lucille P. Markey Cancer Center at University of Kentucky", 
            "last_name": "Susanne M Arnold, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Complete response rate in patients treated with 2 cycles of induction Docetaxel and Carboplatin with low dose fractionated radiation therapy (LDFRT) will be compared to those treated with chemotherapy alone.", 
            "measure": "Complete Response Rate", 
            "safety_issue": "No", 
            "time_frame": "Up to 50 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02126969"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Kentucky", 
            "investigator_full_name": "Susanne Arnold", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess overall response rate of patients to 2 cycles of induction Docetaxel and Carboplatin with or without LDFRT", 
                "measure": "Overall Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 50 days"
            }, 
            {
                "measure": "Number of Serious and Non-Serious Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 50 days"
            }, 
            {
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "Up to 50 days"
            }, 
            {
                "measure": "3-year overall survival", 
                "safety_issue": "No", 
                "time_frame": "Year 3"
            }
        ], 
        "source": "University of Kentucky", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Kentucky", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}